Improving the blood-brain barrier in ALS using a protein called Apolipoprotein A1
Targeting Blood-CNS-Barrier in ALS via Apolipoprotein A1
This study is looking at how a protein called ApoA1 might help protect the blood-brain barrier in people with ALS, with the hope of finding new ways to slow down the disease and improve life for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of South Florida NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-10839856 on NIH RePORTER |
What this research studies
This research investigates the role of Apolipoprotein A1 (ApoA1) in repairing the blood-brain barrier (B-CNS-B) in patients with Amyotrophic Lateral Sclerosis (ALS). The study aims to understand how ApoA1 can enhance the survival of endothelial cells, which are crucial for maintaining the integrity of the blood-brain barrier. By using human bone marrow-derived endothelial progenitor cells and assessing their effects on motor neuron health, the research seeks to identify potential therapeutic strategies for ALS. Patients may benefit from insights into new treatments that could slow disease progression and improve quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Amyotrophic Lateral Sclerosis, particularly those experiencing early to moderate symptoms.
Not a fit: Patients with advanced ALS or those who do not have a confirmed diagnosis of the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that help protect motor neurons and improve outcomes for ALS patients.
How similar studies have performed: Previous research has shown promising results in using similar approaches to enhance endothelial cell function and protect against neurodegeneration, indicating potential for success in this novel application.
Where this research is happening
Tampa, United States
- University of South Florida — Tampa, United States (Active)
Researchers
- Principal investigator: Garbuzova-Davis, Svitlana Nicolai — University of South Florida
- Study coordinator: Garbuzova-Davis, Svitlana Nicolai
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.